Multi-omics insights into metastatic pheochromocytomas and paragangliomas: Mechanisms, signatures, and prediction models
A comprehensive map of genetic changes in rare adrenal tumors reveals new targets and identifies why current prediction tools fail, guiding future improvements.
This comprehensive review maps the multi-omics landscape of metastatic pheochromocytoma/paraganglioma, detailing mechanisms beyond SDHB mutation including immunosuppressive microenvironment and metabolic reprogramming. Existing clinical scoring systems show high observer variability and low PPV, while emerging multi-omics prediction models await external validation.
What the study was
- Study design
- Systematic review
- Population
- Patients with pheochromocytoma and paraganglioma (PPGL)
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Hormones (Athens)
Why it surfaced
Thorough review of rare neuroendocrine tumor genomics with translational value; limited by review design and lack of new validated prediction models.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.